We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Roche Touts Strong New Efficacy Data for Multiple Sclerosis Drug
Roche Touts Strong New Efficacy Data for Multiple Sclerosis Drug
Roche has unveiled new data for its multiple sclerosis drug Ocrevus (ocrelizumab) that further supports its ability to hinder disease progression. The positive new findings come shortly after the FDA’s recent approval of Novartis’ Kesimpta (ofatumumab), a drug that could prove to be a formidable rival to Roche’s blockbuster product.